SEC 13F Intelligence

Managers / Q2 2022 · view latest →

Venrock Adviser, LLC

CIK 0001615982 · 7 BRYANT PARK, 23RD FLOOR, NEW YORK, NY, 10018 · 650-475-3734

Reported Value
$554M
Q2 2022
Positions
28
Filings on Record
28
2019–present window
Filed
Aug 15, 2022
original filing

Summary

Venrock Adviser, LLC reported $554M in U.S.-listed holdings across 28 positions for Q2 2022.

Its largest position, 1T7, represents 12.5% of the portfolio.

Compared with Q1 2022, the fund opened 8 new positions and exited 7.

Portfolio Metrics

Turnover
+28.4%
vs prior filed quarter
Top-10 Concentration
+73.0%
share of reported value
Largest Position
+12.5%
Tricida
New / Exited
8 / 7
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q1 ’20: $369MQ1 ’20Q2 ’20: $418MQ3 ’20: $511MQ4 ’20: $680MQ1 ’21: $922MQ1 ’21Q2 ’21: $824MQ3 ’21: $779MQ4 ’21: $732MQ1 ’22: $617MQ1 ’22Q2 ’22: $554MQ3 ’22: $681MQ4 ’22: $623MQ1 ’23: $512MQ1 ’23Q2 ’23: $625MQ3 ’23: $950MQ4 ’23: $1.5BQ1 ’24: $2.1BQ1 ’24Q2 ’24: $1.6BQ3 ’24: $1.9BQ4 ’24: $1.5BQ1 ’25: $1.2BQ1 ’25Q2 ’25: $1.3BQ3 ’25: $1.8BQ4 ’25: $2.0BQ1 ’26: $2.7BQ1 ’26filingsflow.com

Portfolio Composition

By security type
Common Stock: 71.5%Other: 26.4%ADR: 2.1%
  • Common Stock · 71.5% · $396M
  • Other · 26.4% · $146M
  • ADR · 2.1% · $12M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2022 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
DBV Technologies SANEW+9.30M9.30M+$46M$46M
Inozyme Pharma IncNEW+2.71M2.71M+$13M$13M
Akouos IncNEW+2.67M2.67M+$13M$13M
TRVITrevi Therapeutics IncNEW+3.05M3.05M+$9M$9M
ANNXAnnexon IncNEW+1.93M1.93M+$7M$7M
Lyra Therapeutics IncNEW+924.2K924.2K+$5M$5M
Rallybio CorpNEW+268.5K268.5K+$2M$2M
XENEXenon Pharmaceuticals IncNEW+30.0K30.0K+$913,000$913,000

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2022

28 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
11T7Tricida Inchistory →COM12.46%$69M7.13M
2ACRSAclaris Therapeutics Inchistory →COM11.50%$64M4.56M
3DBV Technologies SASPONS ADR8.35%$46M9.30M
4RLMDRelmada Therapeutics Inchistory →COM7.78%$43M2.27M
5TVTXTravere Therapeutics Inchistory →COM7.48%$41M1.71M
6COGTCogent Biosciences Inchistory →COM6.57%$36M4.04M
7GH Research PLCORD SH5.74%$32M3.19M
8Instil Bio IncCOM5.00%$28M6.00M
9TCE2Celldex Therapeutics Inchistory →COM4.21%$23M865.1K
10VRDNViridian Therapeutics Inchistory →COM3.87%$21M1.85M
11VTGNUSDVistaGen Therapeutics Inchistory →COM3.29%$18M20.70M
12Marinus Pharmaceuticals IncCOM2.76%$15M3.16M
13WHWKAadi Bioscience Inchistory →COM2.61%$14M1.17M
14Inozyme Pharma IncCOM2.33%$13M2.71M
15Akouos IncCOM2.26%$13M2.67M
16LIANYLianBiohistory →SPONS ADR2.10%$12M5.38M
17Aerovate Therapeutics IncCOM1.67%$9M590.4K
18TRVITrevi Therapeutics Inchistory →COM1.55%$9M3.05M
19Chinook Therapeutics IncCOM1.55%$9M489.6K
20ANNXAnnexon Inchistory →COM1.31%$7M1.93M
21YB4PSavara Inchistory →COM1.13%$6M4.12M
22Lyra Therapeutics IncCOM0.94%$5M924.2K
23PRVBUSDProvention Bio IncCOM0.81%$4M1.12M
24ALTAltimmune IncCOM0.78%$4M369.3K
25ATYRaTyr Pharma IncCOM0.71%$4M1.40M
26Affimed NVCOM0.71%$4M1.43M
27Rallybio CorpCOM0.37%$2M268.5K
28XENEXenon Pharmaceuticals IncCOM0.16%$913,00030.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$2.7B33May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$2.0B27Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$1.8B33Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$1.3B31Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$1.2B37May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$1.5B37Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$1.9B38Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$1.6B35Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$2.1B38May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$1.5B36Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$950M37Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$625M30Aug 11, 202313F-HRchanges · EDGAR ↗
Q1 2023$512M25May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$623M29Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$681M32Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$554M28Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$617M27May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$732M26Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$779M26Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$824M29Aug 13, 202113F-HRchanges · EDGAR ↗
Q1 2021$922M28May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$680M25Feb 12, 202113F-HRchanges · EDGAR ↗
Q3 2020$511M22Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$418M16Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$369M16May 15, 202013F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.